• Betaxolol hydrochloride is a topical β1-blocking agent that has been found to be safe and effective in lowering intraocular pressure (IOP) in patients with glaucoma. We administered open-label epinephrine for four weeks to 19 patients who were already being treated with masked 0.5% timolol maleate or 0.5% betaxolol. In patients receiving betaxolol, epinephrine produced a significant additional lowering of mean IOP from 24.5 ± 0.7 to 19.4 ± 0.6 mm Hg at one week (P <.0001) and to 20.7 ± 0.5 mm Hg at four weeks (P <.0001). This was accompanied by a statistically significant increase in mean outflow facility from 0.12 ± 0.1 to 0.17 ± 0.03 μL/min/mm Hg at one week (P ≤.05) and to 0.18 ± 0.02 μl/min/mm Hg at four weeks (P ≤.004). Consistent with previous reports, patients receiving timolol exhibited no significant changes in IOP or outflow facility after the addition of epinephrine to their treatment regimen. These results suggest that epinephrine's agonist effect on the outflow channels is mediated through β2-adrenergic receptors and that combined therapy with betaxolol and epinephrine may be clinically useful.
Allen RC, Epstein DL. Additive Effect of Betaxolol and Epinephrine in Primary Open Angle Glaucoma. Arch Ophthalmol. 1986;104(8):1178–1184. doi:10.1001/archopht.1986.01050200084056
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: